A photoelectric conversion element, including a first electrode, a second electrode, and at least one organic layer being present between the first electrode and the second electrode, in which the organic layer contains at least two kinds of compounds having the same skeletons and different substituents in combination.

The present invention provides useful compounds for HIV protease inhibitor. A compound represented by the following formula or its pharmaceutically acceptable salt:

##STR00001##

wherein ring A is

##STR00002## R.sup.4 is —Y—Z, hydrogen atom, halogen, hydroxy and the like, R.sup.5 is hydrogen atom, halogen, hydroxy and the like, R.sup.6 is each independently halogen, hydroxy, carboxy and the like, ring A may be substituted with said R.sup.6 at any substitutable position(s), a is an integer of 0 to 7, ring B is substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl, ring C is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl, R.sup.1 is —Y—Z, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and the like, R.sup.2 and R.sup.3 are each independently —Y—Z or hydrogen atom, provided that at least one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is a group represented by formula: —Y—Z, Y is a bond, or a spacer of any combination selected from the group consisting of —O—, —S—, —NR.sup.7—, —C(═O)—, —SO—, —SO.sub.2—, —NR.sup.7—C(═O)—, —C(═O)—NR.sup.7—, —NR.sup.7—C(═O)—NR.sup.7—, —O—C(═O)—NR.sup.7—, —NR.sup.7—C(═O)—O—, —SO.sub.2—NR.sup.7—, —NR.sup.7—SO.sub.2—, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted aromatic carbocyclediyl, substituted or unsubstituted non-aromatic carbocyclediyl, substituted or unsubstituted aromatic heterocyclediyl and substituted or unsubstituted non-aromatic heterocyclediyl, R.sup.7 are each independently hydrogen atom, hydroxy, carboxy and the like, and Z is substituted aromatic carbocyclyl, substituted non-aromatic carbocyclyl, substituted aromatic heterocyclyl or substituted non-aromatic heterocyclyl.

The present invention provides useful compounds for HIV protease inhibitor. A compound represented by the following formula or its pharmaceutically acceptable salt:

##STR00001##

wherein ring A is

##STR00002## R.sup.4 is —Y—Z, hydrogen atom, halogen, hydroxy and the like, R.sup.5 is hydrogen atom, halogen, hydroxy and the like, R.sup.6 is each independently halogen, hydroxy, carboxy and the like, ring A may be substituted with said R.sup.6 at any substitutable position(s), a is an integer of 0 to 7, ring B is substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl, ring C is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl, R.sup.1 is —Y—Z, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and the like, R.sup.2 and R.sup.3 are each independently —Y—Z or hydrogen atom, provided that at least one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is a group represented by formula: —Y—Z, Y is a bond, or a spacer of any combination selected from the group consisting of —O—, —S—, —NR.sup.7—, —C(═O)—, —SO—, —SO.sub.2—, —NR.sup.7—C(═O)—, —C(═O)—NR.sup.7—, —NR.sup.7—C(═O)—NR.sup.7—, —O—C(═O)—NR.sup.7—, —NR.sup.7—C(═O)—O—, —SO.sub.2—NR.sup.7—, —NR.sup.7—SO.sub.2—, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted aromatic carbocyclediyl, substituted or unsubstituted non-aromatic carbocyclediyl, substituted or unsubstituted aromatic heterocyclediyl and substituted or unsubstituted non-aromatic heterocyclediyl, R.sup.7 are each independently hydrogen atom, hydroxy, carboxy and the like, and Z is substituted aromatic carbocyclyl, substituted non-aromatic carbocyclyl, substituted aromatic heterocyclyl or substituted non-aromatic heterocyclyl.

Disclosed are amine-substituted naphthalene derivatives and organic light emitting diodes including the same. In the organic light emitting diodes, at least one of the amine-substituted naphthalene derivatives is employed in a hole auxiliary layer interposed between a hole transport layer and a light emitting layer to enable efficient hole transport to the light emitting layer, achieving high luminous efficiency and long lifetime.

The present invention pertains to a material for a photoelectric conversion element for use in an imaging element, the material containing a compound represented by formula (1) (in formula (1), R.sub.1 and R.sub.2 independently represent a substituted or unsubstituted fused heterocyclic aromatic group). The material can provide a photoelectric conversion element having excellent hole and electron leakage preventing properties, hole and electron transport properties, heat tolerance to processing temperatures, and visible light transparency.

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, R.sup.a, R.sup.b, R.sup.c, R.sup.1, L, L.sup.1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. ##STR00001##

The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases. ##STR00001##

A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases. ##STR00001##